ALUMIS INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ALMS in the last 30 days.
See all $ALMS insider activity →Alumis (ALMS) reported its Phase IIb LUMUS trial for envudeucitinib in lupus failed to meet primary and secondary endpoints, causing shares to drop 50%. The trial involved 408 patients and measured disease activity improvement over 48 weeks.
Alumis stock fell 54.2% in pre-market trading after its Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus missed primary and secondary endpoints. A subgroup of patients showed positive responses, but the overall trial population was under-represented. The company plans to discuss a Phase 3 program with regulators. The Nasdaq, S&P 500, and Dow Jones also declined, exacerbating the sell-off.
Alumis Inc. (ALMS) reported that its Phase 2b LUMUS trial of envudeucitinib for systemic lupus erythematosus (SLE) did not meet primary and secondary endpoints in the overall population. However, a prespecified subgroup of patients with high interferon gene signature (IFNGS-high) showed robust responses. The company plans to discuss Phase 3 development with regulators. Envudeucitinib was well tolerated. Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psor
Over the past 7 days, alphai's AI scored 6 news stories mentioning ALMS (ALUMIS INC.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 6 bearish.
Recent ALMS coverage spans technology, financial news and earnings.
Alumis reported a negative Phase IIb trial outcome for its TYK2 inhibitor envudeucitinib in SLE.
The trial failure undermines the drug's market potential and triggers heavy selling pressure.
Negative impact on near-term stock price due to trial failure; potential upside if IFNGS‑high subgroup data leads to Phase 3.
A large new 13D holder can shift perceived control and near-term trading interest, but the filing states no immediate strategic actions.
The filing is a fresh, company-specific ownership and capital-structure update tied to the IPO conversion mechanics and prior large preferred purchases.
alphai scores every news story that mentions ALMS with an AI model for sentiment and relevance, and aggregates insider trades from ALUMIS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Alumis (ALMS) reported its Phase IIb LUMUS trial for envudeucitinib in lupus failed to meet primary and secondary endpoints, causing shares to drop 50%. The trial involved 408 patients and measured disease activity improvement over 48 weeks.
2 min readAlumis stock fell 54.2% in pre-market trading after its Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus missed primary and secondary endpoints. A subgroup of patients showed positive responses, but the overall trial population was under-represented. The company plans to discuss a Phase 3 program with regulators. The Nasdaq, S&P 500, and Dow Jones also declined, exacerbating the sell-off.
2 min readAlumis Inc. (ALMS) reported that its Phase 2b LUMUS trial of envudeucitinib for systemic lupus erythematosus (SLE) did not meet primary and secondary endpoints in the overall population. However, a prespecified subgroup of patients with high interferon gene signature (IFNGS-high) showed robust responses. The company plans to discuss Phase 3 development with regulators. Envudeucitinib was well tolerated. Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psor
2 min readJames B. Tananbaum, via funds managed by Foresite Capital, disclosed a 14.5% stake in Latigo Biotherapeutics, Inc. in a Schedule 13D filed Aug. 17, 2026, after the company’s Aug. 10, 2026 IPO. The filing says there are no current plans for major transactions or board changes, though shares may be bought or sold.
2 min readForesite Capital funds and management, led by James B. Tananbaum, filed a Schedule 13D for Latigo Biotherapeutics (ALMS) common stock, reporting ownership changes after prior purchases of Series A-2 and Series B convertible preferred at set prices and a $3.5M convertible note. A 1-for-6.42441 reverse split occurred July 28, 2026, and preferred converted with Latigo’s Aug. 10 IPO.
6 min readALUMIS INC. (ALMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements – ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO – – Alumis remains on track to
6 min readAlumis Inc. (ALMS) reported long-term extension results from its ONWARD3 study of envudeucitinib, an investigational oral TYK2 inhibitor for plaque psoriasis. It said 54% of patients reached PASI 100 at 48 weeks and 75% reached PASI 90, with durability in responders and no new safety signals. ALMS plans an FDA NDA submission in Q4 2026.
4 min readPangali Sanam (Chief Legal Officer) sold 5,000 shares of ALUMIS INC. (ALMS) at $28.00 ($0.14M total) on 2026-07-06.
1 min readALUMIS INC. (ALMS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001847367 0001847367 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readAlumis Inc. (ALMS) shares drew three analyst price-target raises after its Q1 2026 results and progress on envudeucitinib. Chardan lifted its target to $40 from $38 (Buy), Wells Fargo to $51 from $49 (Overweight), and Guggenheim to $34 from $32 (Buy). The company reported $569.5M cash and narrowed net loss to $93.1M; envudeucitinib Week 24 PASI 90/100 results were also cited.
5 min read
